NovoPro
Cart 2
  • HLA-DRA Polyclonal Antibody
  • HLA-DRA Polyclonal Antibody
  • HLA-DRA Polyclonal Antibody

HLA-DRA Polyclonal Antibody

Cat.#: 166602

Special Price 174.2 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    HLA-DRA Polyclonal Antibody
  • Documents
  • Description
    Polyclonal antibody to HLA-DRA
  • Tested applications
    WB, IHC
  • Species reactivity
    Human
  • Alternative names
    HLA-DRA antibody; HLA-DRA1 antibody; major histocompatibility complex, class II, DR alpha antibody
  • Isotype
    Rabbit IgG
  • Preparation
    Antigen: Recombinant fusion protein containing a sequence corresponding to amino acids 26-216 of human HLA-DRA (NP_061984.2).
  • Clonality
    Polyclonal
  • Formulation
    PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
  • Storage instructions
    Store at -20℃. Avoid freeze / thaw cycles.
  • Applications
    WB 1:500 - 1:2000
    IHC 1:50 - 1:200
  • Validations

    Western blot - HLA-DRA Polyclonal Antibody

    Western blot - HLA-DRA Polyclonal Antibody

    Western blot analysis of extracts of various cell lines, using HLA-DRA antibody at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.

    Immunohistochemistry - HLA-DRA Polyclonal Antibody

    Immunohistochemistry - HLA-DRA Polyclonal Antibody

    Immunohistochemistry of paraffin-embedded human tonsil using HLA-DRA antibody at dilution of 1:100 (40x lens).

    Immunohistochemistry - HLA-DRA Polyclonal Antibody

    Immunohistochemistry - HLA-DRA Polyclonal Antibody

    Immunohistochemistry of paraffin-embedded human liver cancer using HLA-DRA antibody at dilution of 1:100 (40x lens).

  • Background
    Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
  • References

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"